Black women are more likely to experience a delay to follow-up biopsy after abnormal findings on mammography, according to results of a prospective cohort study published in JAMA Oncology.
Researchers evaluated prospective data collected between 2009 and 2019 in the United States for 7 Breast Cancer Surveillance Consortium (BCSC) registries. Differences in time to biopsy after an abnormal mammogram were evaluated on the basis of ethnicity.
The population comprised 45,186 women who had 46,185 screening mammograms with abnormal results. Patients had a median age of 56 years, 65.1% were White, 13.5% were Black, 12.2% were Asian, and 6.6% were Hispanic.
Continue Reading
One-third of abnormal mammograms were not resolved through biopsy or aspiration within 30 days (34.6%), 16.2% were not resolved within 60 days (16.2%), and 12.2% were not resolved within 90 days. The overall median time to biopsy was 23.3 days (IQR, 12.0-45.4 days).
In a fully adjusted model, Asian women (adjusted relative risk [aRR], 1.25), Black women (aRR, 1.24), and Hispanic women (aRR, 1.18) had an increased risk of no biopsy within 30 days, compared with White women. Similar results were observed at 60 days. At 90 days, Hispanic women did not have an increased risk of no biopsy compared with White women, but Black and Asian women remained at increased risk.
Stratified by ethnicity, the adjusted median time to biopsy was 22.7 days for White women, 25.8 days for Hispanic women, 26.7 days for Asian women, and 27.4 days for Black women. These data indicate that the delay to biopsy following an abnormal mammogram was the longest for Black women.
Disclosures: Multiple authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Reference
Lawson MB, Bissell MCS, Miglioretti DL, et al. Multilevel factors associated with time to biopsy after abnormal screening mammography results by race and ethnicity. JAMA Oncol. Published online June 23, 2022. doi:10.1001/jamaoncol.2022.1990
This article originally appeared on Oncology Nurse Advisor
